Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Charles River Laboratories (CRL) Q2 Earnings and Revenues Beat Estimates
01:05pm, Wednesday, 05'th Aug 2020
Charles River (CRL) delivered earnings and revenue surprises of 24.41% and 7.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Charles River: Q2 Earnings Insights
11:53am, Wednesday, 05'th Aug 2020
Shares of Charles River (NYSE:CRL) moved higher by 0.1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 3.07% year over year to $1.58, which
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Could Be 34% Above Their Intrinsic Value Estimate
11:21am, Wednesday, 05'th Aug 2020
Today we will run through one way of estimating the intrinsic value of Charles River Laboratories International, Inc...
Charles River Laboratories Announces Second-Quarter 2020 Results
11:00am, Wednesday, 05'th Aug 2020
Charles River Laboratories Announces Second-Quarter 2020 Results
Agilent Technologies At Upper End Of Buy Range With Earnings Due
09:53pm, Tuesday, 04'th Aug 2020
To build your earnings season watch list, look for stocks in or near a potential buy range ahead of their next report. One company that fits that bill is Agilent Technologies (A). It's expected to rep
Luminex Scores Relative Strength Rating Upgrade
09:39pm, Tuesday, 04'th Aug 2020
Luminex saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 89 to 92. When you're researching the best stocks to buy and watch, keep a close on eye on re
Healthcare Stock Q2 Earnings Roster for Aug 5: HUM, CRL & More
01:41pm, Tuesday, 04'th Aug 2020
The healthcare sector is expected to have benefited from solid demand for medical products and services in Q2, given the rising incidence of coronavirus cases as well as an ageing U.S. populace.
Should You Buy Charles River Laboratories (CRL) Ahead of Earnings?
01:07pm, Tuesday, 04'th Aug 2020
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nothing direct about DSA selection
09:00pm, Sunday, 02'nd Aug 2020
Ahead of this year’s National School Games (NSG), rugby player Jared Khuan was raring to get on the field with his Bukit Batok Secondary School team after he was handed the captain’s armband.. Rea
School Sports: Direct School Admission exercise goes online amid Covid-19 pandemic
11:21am, Sunday, 02'nd Aug 2020
SINGAPORE - Ahead of this year's National School Games (NSG), rugby player Jared Khuan was raring to get out on the field with his Bukit Batok Secondary School team after he was handed the captain's a
Should Investors Buy the Dip in Charles River Laboratories (CRL) Stock?
04:32pm, Friday, 31'st Jul 2020
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Small-Cap Growth Fund posted a return of 34.59% for the quarter, outperforming its benchmark, t
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
04:33pm, Wednesday, 29'th Jul 2020
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gandeng Astra, Mendes optimistis kesejahteraan warga desa meningkat
05:31am, Wednesday, 29'th Jul 2020
Menteri Desa Pembangunan Daerah Tertinggal dan Transmigrasi (Mendes PDTT) Abdul Halim Iskandar optimistis kelanjutan kolaborasi bersama PT Astra melalui ...
Caregiver Inc. Enters a New Partnership With WindRose Health Investors
12:00am, Monday, 27'th Jul 2020
Caregiver has entered a new partnership with WindRose Health Investors to expand into new markets and provide high-quality care to more clients.
Charles River Labs International Trading In New Buy Range With Quarterly Report On Tap
11:39pm, Friday, 24'th Jul 2020
Charles River Labs International (CRL) is in a potential buy area with earnings on tap for Aug. 5. The stock is approximately 2% above a 189.95 buy point from a second-stage flat base. Understand that
